Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정지은 | - |
dc.date.accessioned | 2023-04-25T04:19:43Z | - |
dc.date.available | 2023-04-25T04:19:43Z | - |
dc.date.issued | 2021-06 | - |
dc.identifier.citation | 한국임상약학회지, v. 31.0, NO. 2, Page. 87-95 | - |
dc.identifier.issn | 1226-6051;2508-786X | - |
dc.identifier.uri | https://www.ekjcp.org//journal/view.html?doi=10.24304/kjcp.2021.31.2.87 | en_US |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/179310 | - |
dc.description.abstract | Background: Patients with chronic kidney disease (CKD) are at a high risk of stroke-related morbidity, mortality, and bleeding. However, the overall risk/benefit of anticoagulant therapy among patients with CKD remains unclear. Methods: The MEDLINE, EMBASE, and CENTRAL databases were comprehensively searched until July 31, 2020, to investigate the safety and efficacy of apixaban in patients with stage 4 or 5 CKD, as compared with warfarin. The primary outcome was an incidence of major bleeding. Secondary outcomes included composite bleeding (major, clinically relevant, and minor bleeding), venous thromboembolism (VTE), stroke, and death. Results: In total, seven studies consisting of 10,816 patients were included. Compared with warfarin, apixaban was associated with a reduced risk of major bleeding (OR 0.49, 95% CI 0.41-0.58). In terms of composite bleeding, apixaban tended to pose a significantly lower risk than warfarin (OR 0.51, 95% CI 0.37-0.71). There was no difference between apixaban and warfarin with respect to the risk of stroke or death (stroke: OR 1.23, 95% CI 0.49-3.12; death: OR 0.73, 95% CI 0.45-1.18). Conclusion: Among patients with stage 4 or 5 CKD, the use of apixaban was associated with a lower risk of bleeding compared to warfarin and was also found to pose no excess risk of thromboembolic events. | - |
dc.description.sponsorship | 본 연구는 한국연구재단(과제번호: NRF-2018R1D1A1B 07049959) 및 과학기술정보통신부 정보통신기획평가단(과제번호: 2020-0-01343, 인공지능융합센터, 한양대학교 ERICA)지원을 받아 수행되었으므로 이에 감사드립니다. | - |
dc.language | ko | - |
dc.publisher | 한국임상약학회 | - |
dc.subject | Chronic kidney disease | - |
dc.subject | apixaban | - |
dc.subject | warfarin | - |
dc.subject | bleeding | - |
dc.subject | thromboembolism | - |
dc.title | 만성신장병환자에서 apixaban과 warfarin의 안전성 비교: 체계적 문헌고찰 및 메타분석 | - |
dc.title.alternative | Apixaban versus Warfarin in Patients with Chronic Kidney Disease | - |
dc.title.alternative | A Systematic Review and Meta-analysis | - |
dc.type | Article | - |
dc.relation.no | 2 | - |
dc.relation.volume | 31.0 | - |
dc.identifier.doi | 10.24304/kjcp.2021.31.2.87 | - |
dc.relation.page | 87-95 | - |
dc.relation.journal | 한국임상약학회지 | - |
dc.contributor.googleauthor | 남재현 | - |
dc.contributor.googleauthor | 김채영 | - |
dc.contributor.googleauthor | 이유경 | - |
dc.contributor.googleauthor | 정다움 | - |
dc.contributor.googleauthor | 곽혜영 | - |
dc.contributor.googleauthor | 정지은 | - |
dc.sector.campus | E | - |
dc.sector.daehak | 약학대학 | - |
dc.sector.department | 약학과 | - |
dc.identifier.pid | jechung | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.